(Q35583230)

9 August 2017

title

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort (English)

1 reference

9 August 2017

1 reference

7

Jeffrey R Curtis

1 reference

9 August 2017

Jie Zhang

1

1 reference

9 August 2017

Ying Shan

2

1 reference

9 August 2017

George Reed

3

1 reference

9 August 2017

Joel Kremer

4

1 reference

9 August 2017

Jeffrey D Greenberg

5

1 reference

9 August 2017

Scott Baumgartner

6

1 reference

9 August 2017

publication date

1 December 2011

1 reference

Arthritis Care and Research

9 August 2017

published in

1 reference

9 August 2017

volume

63

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

1672-1679

1 reference

Treating rheumatoid arthritis to target: recommendations of an international task force

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Clinical responses to tumor necrosis factor alpha antagonists do not show a bimodal distribution: data from the Stockholm tumor necrosis factor alpha followup registry

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis

12 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FACR.20643

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FACR.20643

21 January 2018

The CORRONA database.

1 reference

https://api.crossref.org/works/10.1002%2FACR.20643

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FACR.20643

High rates of stopping or switching biological medications in veterans with rheumatoid arthritis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3227763

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

26 September 2018

1 reference

https://api.crossref.org/works/10.1002%2FACR.20643

The patient's perspective and rheumatoid arthritis disease activity indexes

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/21954144

12 December 2020

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/21954144

12 December 2020

Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice

1 reference

https://pubmed.ncbi.nlm.nih.gov/21954144

12 December 2020

Treatment of rheumatoid arthritis: we are getting there

1 reference

https://pubmed.ncbi.nlm.nih.gov/21954144

12 December 2020

Interpreting registry-derived drug studies: does societal context matter?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21954144

12 December 2020

Identifiers

DOI

10.1002/ACR.20643

1 reference

9 August 2017

1 reference

9 August 2017

1 reference